肛門管(SCAC)の扁平上皮がんのためのカルボプラチンとパクリタキセルとともに、レチファンリマブ(Incmga00012)と一緒にレチファンリマブ(incmga00012)へのアクセスを提供する早期アクセスプログラムガイドライン
To provide retifanlimab, on a reactive basis, to adult patients with squamous carcinoma of the anal canal in combination with carboplatin and paclitaxel and who are considered ineligible for other therapeutic options including clinical trials.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
拡張アクセス タイプ
拡張アクセス タイプ
- 個々の患者: 臨床試験に参加できない重篤な疾患または状態の 1 人の患者に、医薬品または生物学的製剤へのアクセスを許可します。それはFDAによって承認されていません。このカテゴリには、緊急事態でのアクセスも含まれます。
- 中規模の集団: 1 人以上の患者 (ただし、一般的には治療 IND/プロトコルよりも少数の患者) が医療機関にアクセスできます。 FDA によって承認されていない医薬品または生物学的製品。このタイプの拡張アクセスは、同じ疾患または状態の複数の患者が、FDA によって承認されていない特定の医薬品または生物学的製品へのアクセスを求めている場合に使用されます。
- 治療 IND/プロトコル
- 治療 IND/プロトコル strong>: FDA によって承認されていない医薬品または生物学的製品への大規模で広範な人口のアクセスを許可します。このタイプの拡張アクセスは、製品が拡張アクセスの使用と同じ用途のマーケティング用に既に開発されている場合にのみ提供できます。
- 個々の患者
連絡先と場所
研究連絡先
研究連絡先
- 名前:Incyte Corporation Call Center (ex-US)
- 電話番号:+800 00027423
- メール:eumedinfo@incyte.com
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Able to comprehend and willing to sign a written ICF for the study.
-
Are 18 years of age or older (or as applicable per local country requirements).
-
Histologically or cytologically verified, inoperable locally recurrent or metastatic SCAC.
-
Adequate ECOG performance status to be able to benefit from the treatment.
-
If HIV-positive, a well controlled and stable disease and receiving antiretroviral therapy (ART/HAART) and have not experienced any HIV-related opportunistic infection for at least 4 weeks prior to study enrollment.
-
Willingness to avoid pregnancy or fathering children based on the criteria below.
- Men must agree to take appropriate precautions to avoid fathering children (with at least 99% certainty) from screening through 120 days after the last dose of INCMGA00012 or placebo or through 180 days after the last dose of chemotherapeutic agents, whichever occurs later (or longer as appropriate based on country-specific requirements) and must refrain from donating sperm during this period. Permitted methods that are at least 99% effective in preventing pregnancy should be communicated to the participants and their understanding confirmed.
- Women of childbearing potential must have a negative serum pregnancy test at screening, agree to take appropriate precautions to avoid pregnancy (with at least 99% certainty), and refrain from donating oocytes from screening through 120 days after the last dose of INCMGA00012 or placebo or through 180 days after the last dose of chemotherapeutic agents, whichever occurs later. Permitted methods that are at least 99% effective in preventing pregnancy should be communicated to the participants and their understanding confirmed. The definition of WOCBP is located in the protocol.
- Women of nonchildbearing potential are eligible as defined in the protocol.
Exclusion Criteria:
- Has received prior PD-(L)1 directed therapy.
- Participants must have recovered from previous therapies for example including but not limited to RT and CRT.
- Participants with laboratory values at screening defined below:
Hematology:
- Platelets < 100 × 109/L.
- Hemoglobin < 9 g/dL.
- ANC < 1.5 x 109/L.
Hepatic:
- ALT ˃ 2.5 x ULN or ˃ 5 x ULN for participants with liver metastases.
- AST ˃ 2.5 x ULN or ˃ 5 x ULN for participants with liver metastases.
- Bilirubin ≥ 1.5 x ULN unless conjugated bilirubin ≤ ULN (conjugated bilirubin only needs to be tested if total bilirubin exceeds ULN). If there is no institutional ULN, then direct bilirubin must be < 40% of total bilirubin.
Renal:
• Calculated creatinine clearance < 50 mL/min calculated by Cockcroft-Gault equation (glomerular filtration rate can also be used in place of CrCl).
Coagulation:
-
INR or PT > 1.5 × ULN, for participants not receiving anticoagulant therapy.
-
aPTT > 1.5 × ULN for participants not receiving anticoagulant therapy.
- Active autoimmune disease requiring systemic immunosuppression in excess of physiologic maintenance doses of corticosteroids (> 10 mg of prednisone or equivalent).
- Evidence of interstitial lung disease or active noninfectious pneumonitis.
- History of organ transplant, including allogeneic stem cell transplantation.
- Known active CNS metastases and/or carcinomatous meningitis, per the protocol.
- Known active HAV, HBV, or HCV infection, as defined by elevated transaminases with the following serology: positivity for HAV IgM antibody, anti-HCV, anti-HBc IgG or IgM, or HBsAg (in the absence of prior immunization).
- Active infections requiring systemic therapy, or IV antibiotic use up to 7 days before Cycle 1 Day 1.
- Known hypersensitivity to platinum, paclitaxel, another monoclonal antibody, or any of the excipients that cannot be controlled with standard measures (eg, antihistamines, corticosteroids).
- Participants with impaired cardiac function or clinically significant cardiac disease as assessed by the treating physician.
- Participant is pregnant or breastfeeding.
- Has pre-existing peripheral neuropathy that is ≥ Grade 2 by CTCAE v5.
- Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant.
研究計画
研究はどのように設計されていますか?
協力者と研究者
出版物と役立つリンク
研究記録日
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- INCMGA00012-EUMA-AC-301
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。